Can neoantigen vaccines scale beyond rare or highly specialized cases?

What was previously believed: Neoantigen vaccines are too slow and expensive for widespread use

For years, the conventional wisdom was that neoantigen vaccines—vaccines tailored to the unique mutations of a single patient's tumor—were a scientific marvel but a logistical dead end. The thinking was that the process of sequencing a tumor, predicting which mutations would trigger an immune response, and manufacturing a custom vaccine for each patient was far too slow, complex, and costly to ever treat more than a handful of people in specialized research centers [5][6]. This view was reinforced by early clinical trials that, while showing promise in melanoma and glioblastoma, were limited to small numbers of patients and required weeks of preparation time [9].

The core problem was the linear mRNA used in early vaccines: it was inherently unstable and required complex modifications to work, making production difficult and limiting how long the vaccine could produce its cancer-fighting proteins inside the body [1]. This made the whole process feel like a bespoke, handcrafted solution—impressive but not scalable.

What we know now: New platforms and 'off-the-shelf' designs are making scale possible

The biggest shift is that new vaccine platforms have solved many of the old stability and production problems. Circular RNA (circRNA) vaccines, for example, are much more stable than linear mRNA because they form a closed loop that resists being broken down by enzymes in the body [1][11]. This means they can be made quickly in a lab without extra chemical modifications, and they produce their cancer-targeting proteins for longer [1]. In mouse models, circRNA neoantigen vaccines packaged in lipid nanoparticles (tiny fat bubbles) triggered strong T-cell immune responses and showed 'superior tumor treatment and prevention' [1]. This is a direct answer to the old scalability problem: a platform that is both more effective and easier to manufacture.

Another major advance is the move toward 'off-the-shelf' neoantigen vaccines. Instead of making a unique vaccine for every patient, researchers are identifying neoantigens that are shared across many patients with the same type of cancer [4][10]. These shared mutations can be turned into standardized vaccines that can be mass-produced and given to many people, especially those at high genetic risk for cancer [10]. This approach is 'advantageous in scalability, cost, and manufacturing timelines' compared to fully personalized vaccines [4]. It's a fundamental shift from a one-at-a-time model to a batch-production model.

Finally, the tools for finding neoantigens have gotten dramatically better. Next-generation sequencing and machine learning algorithms can now scan a tumor's DNA and predict which mutations will make the best vaccine targets much faster and more accurately than even a few years ago [2][7][9]. While prediction is not perfect—there are still false positives and false negatives [5]—the pace of improvement is rapid, and integrating multiple types of data (genomics, proteomics) is boosting accuracy [5]. This means the 'discovery' phase, once a major bottleneck, is becoming faster and more reliable.

What still holds it back: Manufacturing complexity, delivery, and the right clinical setting

Despite the progress, scaling neoantigen vaccines is not a done deal. Manufacturing remains a significant hurdle. Even with better platforms, producing personalized vaccines for each patient is 'complex, time-intensive, and costly,' and needs advances in standardization and automation to become truly scalable [5][6]. The regulatory pathway for personalized medicines is also more complicated than for standard drugs, which adds time and expense [6].

Delivery is another unresolved issue. While lipid nanoparticles work well for mRNA vaccines, the field hasn't settled on a single best delivery system [3]. Different platforms (peptide vaccines, DNA vaccines, viral vectors) each have their own strengths and weaknesses, and no head-to-head comparisons have been done to determine which is best [3]. The way the vaccine is packaged and delivered directly affects how strong the immune response will be [8].

Perhaps most importantly, the clinical setting matters enormously. Neoantigen vaccines appear to work much better when given to patients with a low tumor burden (e.g., after surgery to remove a tumor) than to patients with advanced, widespread cancer [4]. In the metastatic setting, the tumor's own suppressive environment can choke off the vaccine-induced immune response [4]. This means that for now, the most scalable use of these vaccines may be in specific, earlier stages of treatment—not as a universal late-stage therapy. Combining them with immune checkpoint inhibitors (drugs that 'take the brakes off' the immune system) is a promising strategy to overcome this, but the timing and sequencing of such combinations are still being worked out [2][4].

About These Sources

This answer is built on 11 peer-reviewed studies — published from 2021 to 2026, 10 from 2024 or later, 5 in Q1 journals, collectively cited 84 times — selected as the most relevant from 12 studies that passed quality screening, drawn from 60 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions